Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir-Reference-Cited by-同舟云学术

Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir

Published:2023-07-24 Issue:8 Volume:9 Page:1658-1669
ISSN:2374-7943
Container-title:ACS Central Science
language:en
Short-container-title:ACS Cent. Sci.

Author:

Hu Yanmei¹,Lewandowski Eric M.²,Tan Haozhou¹,Zhang Xiaoming³⁴,Morgan Ryan T.²^ORCID,Zhang Xiujun²,Jacobs Lian M. C.²,Butler Shane G.²,Gongora Maura V.²,Choy John⁵,Deng Xufang³⁴,Chen Yu²,Wang Jun¹^ORCID

Affiliation:

1. Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, New Brunswick, New Jersey 08854, United States

2. Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida 33612, United States

3. Department Physiological Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, Oklahoma 74078, United States

4. Oklahoma Center for Respiratory and Infectious Diseases, Oklahoma State University, Stillwater, Oklahoma 74078, United States

5. Department Biology, School of Arts and Sciences, the Catholic University of America, Washington, DC 20064, United States

Funder

National Institute of Allergy and Infectious Diseases

Oklahoma State University

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

General Chemical Engineering,General Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acscentsci.3c00538

Reference43 articles.

1. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

2. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

3. What coronavirus 3C‐like protease tells us: From structure, substrate selectivity, to inhibitor design

4. SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies

5. A tale of two antiviral targets─and the COVID-19 drugs that bind them. https://www.nature.com/articles/d41573-021-00202-8. Accessed on July, 26, 2023.

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions;European Journal of Medicinal Chemistry;2024-11

2. Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system;Antiviral Research;2024-11

3. Structural Basis of Main Proteases of Coronavirus Bound to Bofutrelvir;Journal of Molecular Biology;2024-11

4. Structural and virologic mechanism of the emergence of resistance to M ^pro inhibitors in SARS-CoV-2;Proceedings of the National Academy of Sciences;2024-09-05

5. A Gaussia luciferase reporter assay for the evaluation of coronavirus Nsp5/3CLpro activity;Scientific Reports;2024-09-05